Holly Dubbs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Holly Dubbs has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Xilma Rosa Ortiz-Gonzalez
Division of Neurology, Children's Hospital of Philadelphia, PA; and
3 shared publications Amy Pizzino
Division of Neurology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2 shared publicationsArastoo Vossough
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publicationsDong Li
Division of Human Genetics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2 shared publications- Elaine H. Zackai
The Children's Hospital of Philadelphia, Philadelphia, PA, USA
2 shared publications Eric D. Marsh
Division of Child Neurology, Children's Hospital of Philadelphia, Department of Neurology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3)
Stratification of Phenotypes in Childhood-Onset COL4A1/COL4A2 –Related Disorders Based on Age of Presentation
Variants in COL4A1 and COL4A2 are associated with a multisystem disorder characterized by prominent neurologic involvement that includes intracranial hemorrhages, white matter injury, neurodevelopmental impairment, and epilepsy. The phenotypic spectrum, however, is broad, and disease subgroups have not been robustly identified. The objective of this study was to distinguish pediatric subgroups based on age at symptom onset. This was a retrospective cohort study of pediatric patients with variants in COL4A1 or COL4A2 seen at a single center between January 2008 and October 2024. Patients were included if they had likely pathogenic/pathogenic variants or variants of uncertain significance with consistent clinical phenotype and were followed for ≥6 months. Medical records, laboratory data, and neuroimaging were reviewed. Patients were stratified by age at symptom onset into perinatal, early childhood, and late childhood onset (up to 28 days, up to 4 years, and up to 18 years, respectively). Of the 44 patients meeting inclusion criteria, 33 had variants in COL4A1, 10 in COL4A2, and 1 in both. Neurologic features, such as global developmental delay, cerebral palsy, and epilepsy, were common in perinatal and early childhood cases. In COL4A1-related disease, such neurologic features were present in 14/17 and 8/9 cases, respectively. These features similarly occurred in all patients with perinatal (n = 3) and early childhood (n = 6) onset of COL4A2-related disease. Conversely, these manifestations were less common in late childhood presentations of either disorder (n = 6 total), occurring in 33% of patients. Extracentral nervous system manifestations, particularly ocular abnormalities and renal disease, were predominantly seen in COL4A1-related disease. Neuroimaging in perinatal and early childhood presentations frequently demonstrated periventricular hemorrhagic infarction (20/26 and 6/9 of COL4A1 and COL4A2 patients). Isolated leukoencephalopathy was universally present in late childhood onset patients. The pediatric phenotype of COL4A1/2-related disorder varies by age at disease onset. Perinatal and early childhood presentations (≤4 years) have a prominent neurologic phenotype with severe developmental delays, cerebral palsy, and epilepsy, correlating on imaging with sequelae from brain injury during prenatal brain development. Late childhood presentations (>4 years) have a milder phenotype, typically with isolated leukoencephalopathy on imaging.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3)
Open AccessStratification of Phenotypes in Childhood-Onset COL4A1/COL4A2 –Related Disorders Based on Age of Presentation
Variants in COL4A1 and COL4A2 are associated with a multisystem disorder characterized by prominent neurologic involvement that includes intracranial hemorrhages, white matter injury, neurodevelopmental impairment, and epilepsy. The phenotypic spectrum, however, is broad, and disease subgroups have not been robustly identified. The objective of this study was to distinguish pediatric subgroups based on age at symptom onset. This was a retrospective cohort study of pediatric patients with variants in COL4A1 or COL4A2 seen at a single center between January 2008 and October 2024. Patients were included if they had likely pathogenic/pathogenic variants or variants of uncertain significance with consistent clinical phenotype and were followed for ≥6 months. Medical records, laboratory data, and neuroimaging were reviewed. Patients were stratified by age at symptom onset into perinatal, early childhood, and late childhood onset (up to 28 days, up to 4 years, and up to 18 years, respectively). Of the 44 patients meeting inclusion criteria, 33 had variants in COL4A1, 10 in COL4A2, and 1 in both. Neurologic features, such as global developmental delay, cerebral palsy, and epilepsy, were common in perinatal and early childhood cases. In COL4A1-related disease, such neurologic features were present in 14/17 and 8/9 cases, respectively. These features similarly occurred in all patients with perinatal (n = 3) and early childhood (n = 6) onset of COL4A2-related disease. Conversely, these manifestations were less common in late childhood presentations of either disorder (n = 6 total), occurring in 33% of patients. Extracentral nervous system manifestations, particularly ocular abnormalities and renal disease, were predominantly seen in COL4A1-related disease. Neuroimaging in perinatal and early childhood presentations frequently demonstrated periventricular hemorrhagic infarction (20/26 and 6/9 of COL4A1 and COL4A2 patients). Isolated leukoencephalopathy was universally present in late childhood onset patients. The pediatric phenotype of COL4A1/2-related disorder varies by age at disease onset. Perinatal and early childhood presentations (≤4 years) have a prominent neurologic phenotype with severe developmental delays, cerebral palsy, and epilepsy, correlating on imaging with sequelae from brain injury during prenatal brain development. Late childhood presentations (>4 years) have a milder phenotype, typically with isolated leukoencephalopathy on imaging.
- Open Access
Genetic testing for familial epilepsies: Diagnostic yield and genetic findings
Objective: Genetic testing has become a routine part of clinical epilepsy care. Family history is an indication for genetic testing, but the diagnostic yield, predictors of a genetic diagnosis, and association with familial patterns are not well understood. Methods: This was a retrospective cohort study of genetic testing performed at pediatric and adult epilepsy genetics clinics. Eligible patients (probands) had epilepsy and one or more first‐degree relatives or two or more other relatives with epilepsy. Genetic testing strategies were patient specific, reflecting real‐world clinical practice. Familial patterns were classified based on affected relatives of the proband. Diagnostic variants were tested in the proband's parents when possible. Results: We studied 484 probands and their families. A genetic diagnosis was identified in 99 of 484 (20%). Predictors of a genetic diagnosis were presence of neurodevelopmental disorder ( X 2 (1) = 9.6, p = .002) and earlier age at seizure onset (Mann–Whitney U test, p < .001). The likelihood of a genetic diagnosis was not associated with epilepsy type, drug resistance, brain magnetic resonance imaging (MRI) findings, number of affected first‐degree relatives, total number of affected relatives, or having an affected parent with epilepsy. Among those with genetic diagnoses, variant segregation matched the familial pattern of affected individuals in 79%. The other 21% of families had unexpected segregation, including de novo variants in patients with affected ancestors and inherited variants in patients with no known affected ancestors. Significance: Familial epilepsy has a substantial rate of genetic diagnosis and is an appropriate indication for genetic testing. Pedigree‐related factors did not influence the likelihood of genetic diagnosis, suggesting that all families can be considered for genetic testing, independent of inheritance patterns and number of affected relatives. Familial patterns can help interpret genetic test results, while also revealing the complexities of incomplete penetrance and independent epilepsy etiologies in families.
Open AccessGenetic testing for familial epilepsies: Diagnostic yield and genetic findings
Objective: Genetic testing has become a routine part of clinical epilepsy care. Family history is an indication for genetic testing, but the diagnostic yield, predictors of a genetic diagnosis, and association with familial patterns are not well understood. Methods: This was a retrospective cohort study of genetic testing performed at pediatric and adult epilepsy genetics clinics. Eligible patients (probands) had epilepsy and one or more first‐degree relatives or two or more other relatives with epilepsy. Genetic testing strategies were patient specific, reflecting real‐world clinical practice. Familial patterns were classified based on affected relatives of the proband. Diagnostic variants were tested in the proband's parents when possible. Results: We studied 484 probands and their families. A genetic diagnosis was identified in 99 of 484 (20%). Predictors of a genetic diagnosis were presence of neurodevelopmental disorder ( X 2 (1) = 9.6, p = .002) and earlier age at seizure onset (Mann–Whitney U test, p < .001). The likelihood of a genetic diagnosis was not associated with epilepsy type, drug resistance, brain magnetic resonance imaging (MRI) findings, number of affected first‐degree relatives, total number of affected relatives, or having an affected parent with epilepsy. Among those with genetic diagnoses, variant segregation matched the familial pattern of affected individuals in 79%. The other 21% of families had unexpected segregation, including de novo variants in patients with affected ancestors and inherited variants in patients with no known affected ancestors. Significance: Familial epilepsy has a substantial rate of genetic diagnosis and is an appropriate indication for genetic testing. Pedigree‐related factors did not influence the likelihood of genetic diagnosis, suggesting that all families can be considered for genetic testing, independent of inheritance patterns and number of affected relatives. Familial patterns can help interpret genetic test results, while also revealing the complexities of incomplete penetrance and independent epilepsy etiologies in families.
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (1)
Expanding the Early Childhood Manifestations of ITPR1 Heterozygous Variants Beyond Congenital Ataxia and Gillespie Syndrome
Heterozygous ITPR1 variants have been previously linked to multiple human disease phenotypes, including congenital ataxia and Gillespie syndrome. Previous reports have described potential genotype-phenotype correlations, yet at a functional level, the mechanisms underlying the clinical variability remain unclear. The aim of this study was to expand the known phenotypic spectrum of ITPR1 variants by describing a case series of pediatric patients with clinical presentations distinct from those previously reported. We also functionally tested the effects of a novel ITPR1 missense variant on calcium cellular dynamics. Clinical data were collected by retrospective chart review at a single center. Functional studies to test the effect of the p.Gly2539Trp novel missense variant were performed in vitro to assess the subcellular distribution of the encoded IP3R type 1 protein, as well as the channel's calcium activity. We identified 3 pediatric patients with heterozygous ITPR1 variants [c.7615G>T (p.Gly2539Trp), a 7.116-Mb deletion of 3p26.1p26.3 including ITPR1, and c.7900T>C (p.Tyr2634His)] without evidence of congenital ophthalmologic abnormalities or ataxia. Patients exhibited a range of symptoms, including language delays, autism spectrum disorder, and exercise intolerance. Functionally, we show that although the p.Gly2539Trp variant does not affect the subcellular distribution of the channel, it does abolish agonist-induced calcium release. Our data support an expansion of the clinical phenotype of the pediatric presentation of ITPR1 variants, highlighting cognitive difficulties, autism, and a later onset of ataxia in childhood. We also provide evidence for the pathogenicity of the novel heterozygous p.Gly2539Trp variant by a loss-of-function mechanism.
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (1)
Open AccessExpanding the Early Childhood Manifestations of ITPR1 Heterozygous Variants Beyond Congenital Ataxia and Gillespie Syndrome
Heterozygous ITPR1 variants have been previously linked to multiple human disease phenotypes, including congenital ataxia and Gillespie syndrome. Previous reports have described potential genotype-phenotype correlations, yet at a functional level, the mechanisms underlying the clinical variability remain unclear. The aim of this study was to expand the known phenotypic spectrum of ITPR1 variants by describing a case series of pediatric patients with clinical presentations distinct from those previously reported. We also functionally tested the effects of a novel ITPR1 missense variant on calcium cellular dynamics. Clinical data were collected by retrospective chart review at a single center. Functional studies to test the effect of the p.Gly2539Trp novel missense variant were performed in vitro to assess the subcellular distribution of the encoded IP3R type 1 protein, as well as the channel's calcium activity. We identified 3 pediatric patients with heterozygous ITPR1 variants [c.7615G>T (p.Gly2539Trp), a 7.116-Mb deletion of 3p26.1p26.3 including ITPR1, and c.7900T>C (p.Tyr2634His)] without evidence of congenital ophthalmologic abnormalities or ataxia. Patients exhibited a range of symptoms, including language delays, autism spectrum disorder, and exercise intolerance. Functionally, we show that although the p.Gly2539Trp variant does not affect the subcellular distribution of the channel, it does abolish agonist-induced calcium release. Our data support an expansion of the clinical phenotype of the pediatric presentation of ITPR1 variants, highlighting cognitive difficulties, autism, and a later onset of ataxia in childhood. We also provide evidence for the pathogenicity of the novel heterozygous p.Gly2539Trp variant by a loss-of-function mechanism.
- 28 August 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (1) , e63843
Deletions in the CDKL5 5′ untranslated region lead to CDKL5 deficiency disorder
Pathogenic variants in the cyclin‐dependent kinase‐like 5 (CDKL5) gene are associated with CDKL5 deficiency disorder (CDD), a severe X‐linked developmental and epileptic encephalopathy. Deletions affecting the 5′ untranslated region (UTR) of CDKL5, which involve the noncoding exon 1 and/or alternatively spliced first exons (exons 1a–e), are uncommonly reported. We describe genetic and phenotypic characteristics for 15 individuals with CDKL5 partial gene deletions affecting the 5′ UTR. All individuals presented characteristic features of CDD, including medically refractory infantile‐onset epilepsy, global developmental delay, and visual impairment. We performed RNA sequencing on fibroblast samples from three individuals with small deletions involving exons 1 and/or 1a/1b only. Results demonstrated reduced CDKL5 mRNA expression with no evidence of expression from alternatively spliced first exons. Our study broadens the genotypic spectrum for CDD by adding to existing evidence that deletions affecting the 5′ UTR of the CDKL5 gene are associated with the disorder. We propose that smaller 5′ UTR deletions may require additional molecular testing approaches such as RNA sequencing to determine pathogenicity.
- 28 August 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (1) , e63843
Deletions in the CDKL5 5′ untranslated region lead to CDKL5 deficiency disorder
Pathogenic variants in the cyclin‐dependent kinase‐like 5 (CDKL5) gene are associated with CDKL5 deficiency disorder (CDD), a severe X‐linked developmental and epileptic encephalopathy. Deletions affecting the 5′ untranslated region (UTR) of CDKL5, which involve the noncoding exon 1 and/or alternatively spliced first exons (exons 1a–e), are uncommonly reported. We describe genetic and phenotypic characteristics for 15 individuals with CDKL5 partial gene deletions affecting the 5′ UTR. All individuals presented characteristic features of CDD, including medically refractory infantile‐onset epilepsy, global developmental delay, and visual impairment. We performed RNA sequencing on fibroblast samples from three individuals with small deletions involving exons 1 and/or 1a/1b only. Results demonstrated reduced CDKL5 mRNA expression with no evidence of expression from alternatively spliced first exons. Our study broadens the genotypic spectrum for CDD by adding to existing evidence that deletions affecting the 5′ UTR of the CDKL5 gene are associated with the disorder. We propose that smaller 5′ UTR deletions may require additional molecular testing approaches such as RNA sequencing to determine pathogenicity.
- Open Access
- 19 July 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (12) , e63817
Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes
Exome sequencing (ES) has emerged as an essential tool in the evaluation of neurodevelopmental disorders (NDD) of unknown etiology. Genome sequencing (GS) offers advantages over ES due to improved detection of structural, copy number, repeat number and non‐coding variants. However, GS is less commonly utilized due to higher cost and more intense analysis. Here, we present nine cases of pediatric NDD that were molecularly diagnosed with GS between 2017 and 2022, following non‐diagnostic ES. All individuals presented with global developmental delay or regression. Other features present in our cohort included epilepsy, white matter abnormalities, brain malformation and dysmorphic features. Two cases were diagnosed on GS due to newly described gene‐disease relationship or variant reclassification (MAPK8IP3, CHD3). Additional features missed on ES that were later detected on GS were: intermediate‐size deletions in three cases who underwent ES that were not validated for CNV detection, pathogenic variants within the non‐protein coding genes SNORD118 and RNU7‐1, pathogenic variant within the promoter region of GJB1, and a coding pathogenic variant within BCAP31 which was not sufficiently covered on ES. GS following non‐diagnostic ES led to the identification of pathogenic variants in this cohort of nine cases, four of which would not have been identified by reanalysis alone.
- 19 July 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (12) , e63817
Open AccessUtility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes
Exome sequencing (ES) has emerged as an essential tool in the evaluation of neurodevelopmental disorders (NDD) of unknown etiology. Genome sequencing (GS) offers advantages over ES due to improved detection of structural, copy number, repeat number and non‐coding variants. However, GS is less commonly utilized due to higher cost and more intense analysis. Here, we present nine cases of pediatric NDD that were molecularly diagnosed with GS between 2017 and 2022, following non‐diagnostic ES. All individuals presented with global developmental delay or regression. Other features present in our cohort included epilepsy, white matter abnormalities, brain malformation and dysmorphic features. Two cases were diagnosed on GS due to newly described gene‐disease relationship or variant reclassification (MAPK8IP3, CHD3). Additional features missed on ES that were later detected on GS were: intermediate‐size deletions in three cases who underwent ES that were not validated for CNV detection, pathogenic variants within the non‐protein coding genes SNORD118 and RNU7‐1, pathogenic variant within the promoter region of GJB1, and a coding pathogenic variant within BCAP31 which was not sufficiently covered on ES. GS following non‐diagnostic ES led to the identification of pathogenic variants in this cohort of nine cases, four of which would not have been identified by reanalysis alone.
- Open Access
- 9 September 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (11) , 2351-2366
Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
- 9 September 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (11) , 2351-2366
Open AccessGenomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
- 7 June 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (9) , 2617-2626
Pathogenic variants in CASK: Expanding the genotype–phenotype correlations
Pathogenic variants in CASK, an X‐linked gene that plays a role in brain development and synaptic function, are the cause of both microcephaly with pontine and cerebellar hypoplasia (MICPCH), and X‐linked intellectual disability (XLID) with or without nystagmus. MICPCH is caused by loss of function variants in CASK, typically affects females, and is associated with moderate‐to‐severe intellectual disability (ID). Additional findings, present in about one‐third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss. Only a few affected males with MICPCH phenotype have been reported and most have had profound developmental disability and intractable epilepsy. The XLID phenotype is typically caused by missense variants and most often manifests in males; carrier females are mildly affected or unaffected. Nystagmus is often present. In total, over 175 patients have been reported in the literature. We now report an additional 11 patients with pathogenic variants in CASK that expand these phenotypes and reported genotype–phenotype correlations.
- 7 June 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (9) , 2617-2626
Pathogenic variants in CASK: Expanding the genotype–phenotype correlations
Pathogenic variants in CASK, an X‐linked gene that plays a role in brain development and synaptic function, are the cause of both microcephaly with pontine and cerebellar hypoplasia (MICPCH), and X‐linked intellectual disability (XLID) with or without nystagmus. MICPCH is caused by loss of function variants in CASK, typically affects females, and is associated with moderate‐to‐severe intellectual disability (ID). Additional findings, present in about one‐third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss. Only a few affected males with MICPCH phenotype have been reported and most have had profound developmental disability and intractable epilepsy. The XLID phenotype is typically caused by missense variants and most often manifests in males; carrier females are mildly affected or unaffected. Nystagmus is often present. In total, over 175 patients have been reported in the literature. We now report an additional 11 patients with pathogenic variants in CASK that expand these phenotypes and reported genotype–phenotype correlations.
- 1 February 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 115, 1-6
Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features
- 1 February 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 115, 1-6
Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features
- 11 March 2020
- Published by Elsevier in Pediatric Neurology
- Vol. 109, 56-62
Phenotypic and Imaging Spectrum Associated With WDR45
- 11 March 2020
- Published by Elsevier in Pediatric Neurology
- Vol. 109, 56-62
Phenotypic and Imaging Spectrum Associated With WDR45
- Open Access
- 21 July 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 167 (12) , 3091-3095
Detection of mutually exclusive mosaicism in a girl with genotype-phenotype discrepancies
Discordance between clinical phenotype and genotype has multiple causes, including mosaicism. Phenotypes can be modified due to tissue distribution, or the presence of multiple abnormal cell lines with different genomic contributions. We have studied a 20‐month‐old female whose main phenotypes were failure to thrive, developmental delay, and patchy skin pigmentation. Initial chromosome and SNP microarray analysis of her blood revealed a non‐mosaic ∼24 Mb duplication of 15q25.1q26.3 resulting from the unbalanced translocation of terminal 15q to the short arm of chromosome 15. The most common feature associated with distal trisomy 15q is prenatal and postnatal overgrowth, which was not consistent with this patient's phenotype. The phenotypic discordance, in combination with the patchy skin pigmentation, suggested the presence of mosaicism. Further analysis of skin biopsies from both hyper‐ and hypopigmented regions confirmed the presence of an additional cell line with the short arm of chromosome X deleted and replaced by the entire long arm of chromosome 15. The Xp deletion, consistent with a variant Turner Syndrome diagnosis, better explained the patient's phenotype. Parental studies revealed that the alterations in both cell lines were de novo and the duplicated distal 15q and the deleted Xp were from different parental origins, suggesting a mitotic event. The possible mechanism for the occurrence of two mutually exclusive structural rearrangements with both involving the long arm of chromosome 15 is discussed.
- 21 July 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 167 (12) , 3091-3095
Open AccessDetection of mutually exclusive mosaicism in a girl with genotype-phenotype discrepancies
Discordance between clinical phenotype and genotype has multiple causes, including mosaicism. Phenotypes can be modified due to tissue distribution, or the presence of multiple abnormal cell lines with different genomic contributions. We have studied a 20‐month‐old female whose main phenotypes were failure to thrive, developmental delay, and patchy skin pigmentation. Initial chromosome and SNP microarray analysis of her blood revealed a non‐mosaic ∼24 Mb duplication of 15q25.1q26.3 resulting from the unbalanced translocation of terminal 15q to the short arm of chromosome 15. The most common feature associated with distal trisomy 15q is prenatal and postnatal overgrowth, which was not consistent with this patient's phenotype. The phenotypic discordance, in combination with the patchy skin pigmentation, suggested the presence of mosaicism. Further analysis of skin biopsies from both hyper‐ and hypopigmented regions confirmed the presence of an additional cell line with the short arm of chromosome X deleted and replaced by the entire long arm of chromosome 15. The Xp deletion, consistent with a variant Turner Syndrome diagnosis, better explained the patient's phenotype. Parental studies revealed that the alterations in both cell lines were de novo and the duplicated distal 15q and the deleted Xp were from different parental origins, suggesting a mitotic event. The possible mechanism for the occurrence of two mutually exclusive structural rearrangements with both involving the long arm of chromosome 15 is discussed.